近年来中国的介入式医疗器械市场增长迅速，且有望于最近将来保持增长趋势。此外，中国在经皮冠状动脉介入治疗手术中使用的治疗器械主要为早期产品(如裸金属支架(BMS)或药物洗脱支架(DES))，显示先进产品(如全降解支架)享有巨大市场。According to the disclosure of the Hong Kong Stock Exchange on June 16, Shanghai Baixinan Biotechnology Co., Ltd. (Bai Xin an) was heard by the Hong Kong Stock Exchange, with Goldman Sachs Group and Huatai International as its co-sponsors, Zhitong Financial APP learned.
According to the prospectus, the company is China's leading interventional cardiovascular device company, currently focusing on the following two treatments: (I) fully degradable stents (BRS) to address the unmet medical needs of Chinese patients for the treatment of coronary or peripheral artery disease; and (ii) renal nerve occlusion (RDN) to address patients' unmet medical needs for the treatment of uncontrolled hypertension.
China's market for invasive medical devices has grown rapidly in recent years and is expected to maintain its growth trend in the near future. In addition, the therapeutic instruments used in percutaneous coronary intervention in China are mainly early products (such as bare metal stents (BMS) or drug-eluting stents (DES)), indicating a huge market for advanced products such as fully degradable stents.
The company's core product, Bioheart ®, is a self-developed fully degradable stent system used in percutaneous coronary intervention for the treatment of coronary artery disease. According to Frost Sullivan, the company is one of only three domestic companies in China with second-generation fully degradable stent products in clinical trials and one of only two domestic companies that have launched randomized controlled clinical trials (RCT) in China.
Similarly, in terms of the renal nerve blocking market, despite the large and rapidly growing number of hypertensive patients and the limited number of proven clinical treatments for uncontrolled or intractable hypertension, and renal nerve blocking therapy has an advantage over traditional therapy, there are no commercialized renal nerve blocking products in China.
According to Frost Sullivan, the company is one of only three companies in China that have renal nerve blocking products in clinical trials, and its second-generation Iberis ®is expected to be the first approved multi-electrode renal nerve blocking product in China.
Both Bioheart ®and the second generation Iberis ®have been recognized as "innovative medical devices" by the State Drug Administration and are eligible for a rapid approval process. In addition, the company has reached a strategic partnership with Telmao, one of the world's leading manufacturers of medical devices and products.
On the financial front, the prospectus revealed that the company currently had no products approved for commercial sale and did not generate any revenue from product sales during the track record period. The company lost 23.719 million yuan in 2019 and 340 million yuan in 2020.
